ERBB2 and breast cancer: Based on the updated survival data in the phase I trials, the median PFS was 8.2 months (95% CI: 5.6–10.9 months) in the pyrotinib monotherapy cohort and 22.1 months (95% CI: 14.3–29.9 months) in the pyrotinib plus capecitabine cohort, indicating promising antitumor activity in HER2-positive breast cancer.